DTcP vaccine is for infants (below 2 years old), addresses the weaker protection preventing pertussis after primary vaccination. We are developing a potential China best-in-class DTcP vaccine for infants. 

As compared with the co-purified DTaP vaccines,  ourDTcP Infant candidate demonstrates fewer sideeffects and conveys better and more consistent immunogenicity. As compared with Pentaxim, which is the only vaccine in China with a DTcP component, our DTcP Infant candidate demonstrated better immunogenicity in pre-clinical studies. Our DTcP Infant candidate received CTA approval in 2018. We have already completed the phase I clinical trial.